GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

AbbVie

Bristol-Myers

Gilead Sciences

Johnson & Johnson

Novartis

Merck

So, which pharmaceutical stocks should be on your radar, if dividends are a top priority? Consider these seven compelling opportunities.

7 Pharmaceutical Stocks With Dividends in Hand

Although the COVID-19 pandemic has given quite the boost to several companies in the healthcare sector, GlaxoSmithKline PLC (LON:GSK) has emerged as the unlikely loser. Despite its focus on vaccines, which accounted for 17% of total sales in the first quarter, the pharma giant has remained somewhat on the sidelines of the race to find a COVID-19 jab.

GlaxoSmithKline emerges as unlikely loser of COVID-19 pandemic – but will a return to normality be enough to sort out trouble?

GlaxoSmithKline Plc (NYSE: GSK) Q1 revenue fell 18% in the first quarter, as the COVID-19 vaccination program delayed sales of its Shingrix shot for shingles. Earnings: The company reported sales of £7.4 billion, down from £9.1 billion a year ago, as the COVID-19 pandemic hit all the operating segments.

GlaxoSmithKline Q1 Profit, Sales Decline As COVID-19 Vaccination Delay Other Treatments; Backs 2021 Outlook

Glaxo miss earnings as well as revenues estimates in the first quarter of 2021. Stock down.

Glaxo (GSK) Miss Earnings and Revenues Estimates in Q1

GlaxoSmithKline PLC (LON:GSK) has reiterated guidance, hoping that healthcare systems and consumer trends will approach normality in the second half of the year, after posting weak first-quarter results. Turnover is expected to be either flat or rise up to 2% for the Pharmaceuticals and Vaccines businesses, and advance by 2-5% for Consumer Healthcare excluding brands divested and under review.

GlaxoSmithKline pins hopes on return to normality as quarterly turnover slides

GlaxoSmithKline stock ticked higher on Wednesday after the British drugmaker beat profit expectations and said progress had been made on plans to split the company into two. GlaxoSmithKline reported turnover of £7.42 billion ($10.26 billion) in the first quarter, a 15% fall on the previous year at constant exchange rates, missing consensus estimates for £7.83 billion.

GlaxoSmithKline delivers profit beat, but sales disappoint

Plans for GSK to split in two are "well underway" it said on Wednesday, as a cost clampdown and rising clinic visits for critical treatments after an easing of COVID-19 curbs helped it land better-than-forecast first-quarter earnings.

GSK focused on split as cost checks, COVID-19 easings aid earnings

GlaxoSmithKline PLC (LON:GSK) is set to drop its quarterly results at a time of turmoil, as activist hedge fund Elliot is understood to have built up a significant stake. The pharma giant is unlikely to comment much on the new addition shareholder roster, but investors are expecting more news on the horizon as Elliot is known to be a catalyst for change.

GlaxoSmithKline to drop quarterly results as Elliot presence signals it's time for change

GlaxoSmithKline (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy GlaxoSmithKline (GSK) Ahead of Earnings?

Apple

J Sainsbury PLC

Lloyds Banking Group

The mid-point of the week will be in keeping with the busy theme of the preceding days, with trading updates due from banking giant Lloyds and pharma firm GSK alongside results from supermarket chain Sainsbury's. It will also be a busy day over in the US with earnings from Apple and Facebook competing for investor attention alongside the latest interest rates decision from the Federal Reserve.

Lloyds, GSK and Sainsbury's among mid-week reporters, Apple and Facebook earnings eyed alongside the Fed

AstraZeneca

GlaxoSmithKline Plc and AstraZeneca Plc publish quarterly results this week, with Britain's two biggest drugmakers both facing pressure from different quarters.

Vaccines, management in focus as GSK, AstraZeneca report

Bayer AG

Biogen

British American Tobacco

Imperial Brands PLC

Lockheed Martin

Philip Morris

Roche Holding AG

Sanofi

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). e are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The May 2021 Heat Map

The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating women with recurrent or advanced dMMR endometrial cancer.

Glaxo (GSK) Gets FDA Nod for Endometrial Cancer Drug Jemperli

GlaxoSmithKline presents a great opportunity for investors this year.

1 Cheap Pharmaceutical Stock to Buy in 2021

GlaxoSmithKline PLC (LON:GSK) said the US Food and Drug Administration (FDA) has approved its treatment for adults with recurrent or advanced endometrial cancer. JEMPERLI (dostarlimab-gxly) is an antibody that blocks the interaction between the PD-1 receptor with two other proteins that suppress the immune system.

GlaxoSmithKline receives US approval for endometrial cancer treatment

LONDON, April 22, 2021 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved JEMPERLI (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the company's Biologics License Application. JEMPERLI is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that have progressed on or following prior treatment with a platinum-containing regimen.

FDA grants accelerated approval for GSK's JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer

U.S.-listed shares of GlaxoSmithKline were down 1.4% in trading on Thursday after the Food and Drug Administration said it had granted accelerated approval to the company's endometrial cancer treatment. The immunotherapy, which was called dostarlimab and is now named Jemperli, is approved to treat patients with severe forms of this kind of cancer who have a genetic feature known as dMMR.

FDA approves GSK's endometrial cancer therapy

The FDA has granted accelerated approval to GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab) for endometrial cancer. The approval covers patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR.

GlaxoSmithKline's Immunotherapy For Endometrial Cancer Wins FDA Approval

Vectura Group PLC (LON:VEC) confirmed that the patent litigation with GlaxoSmithKline PLC (LON:GSK) is now fully resolved and noted Hikma Pharmaceuticals PLC's launch of generic Advair Diskus. GSK has not petitioned the Supreme Court concerning the Ellipta products for asthma and chronic obstructive pulmonary disease, which would have been the final route of appeal.

Vectura confirms GlaxoSmithKline patent litigation is over, notes Hikma's launch of generic Advair Diskus

GlaxoSmithKline PLC's (LON:GSK) spinoff is expected to deliver above-sector sales growth contrary to market scepticism, analysts at Liberum said. The FTSE 100 group plans to split into two companies in 2022, consumer health and biopharma, and the outlook for the latter is regarded as the benchmark for the success of the spinoff.

GlaxoSmithKline biopharma spinoff to deliver solid sales growth contrary to market scepticism, says City broker

It looks like GlaxoSmithKline PLC (NYSE:GSK) has poked the bear.

Activist Investor Seeking to Shake Things Up at Glaxo

Analysts at Bank of America say they're not sure what steps GlaxoSmithKline could take under an activist's influence that the company isn't already doing.

Glaxo Jumped on Report of Activist Stake. But What Could Elliott Management Do?

The stock rose 7.6% on Thursday on hopes a shake-up could add value but it is flat now.

Activist Investor Elliott Builds Stake in GlaxoSmithKline, According to Reports

Vir Biotechnology

The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.

Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU

Eli Lilly

Regeneron Pharmaceuticals

UnitedHealth Group

"I think that the left-behind health care stocks are now coming back to life at the expense of the cyclical growth plays," the "Mad Money" host said.

Health-care stocks are making a comeback, Jim Cramer says

News for GlaxoSmithKline Stock (GSK)